{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:02:25Z","timestamp":1779264145611,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis Supplements"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.atherosclerosissup.2012.10.017","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T17:33:51Z","timestamp":1359221631000},"page":"29-32","source":"Crossref","is-referenced-by-count":15,"title":["Lipoprotein apheresis \u2013 More than just cholesterol reduction?"],"prefix":"10.1016","volume":"14","author":[{"given":"Claas L.","family":"Neumann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egbert G.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerit C.","family":"Hagenah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Platzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Wieland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Schettler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2004.11.007","article-title":"Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins","volume":"180","author":"Geiss","year":"2005","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0002-9149(94)90461-8","article-title":"Indications for low-density lipoprotein apheresis","volume":"74","author":"Gordon","year":"1994","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1526-0968.2002.00426.x","article-title":"First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management","volume":"6","author":"Schettler","year":"2002","journal-title":"Ther Apher"},{"issue":"Suppl\u00a01","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib4","first-page":"15","article-title":"Current view: indications for extracorporeal lipoprotein apheresis treatment","volume":"7","author":"Schettler","year":"2012","journal-title":"Clin Res Cardiol"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11936-004-0027-2","article-title":"Management of hyperlipidemia in the pediatric population","volume":"6","author":"Tonstad","year":"2004","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"12","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.7326\/0003-4819-125-12-199612150-00001","article-title":"Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease","volume":"125","author":"Kroon","year":"1996","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib7","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib8","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0735-1097(02)01955-1","article-title":"Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART)","volume":"40","author":"Matsuzaki","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0021-9150(98)00328-1","article-title":"Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS)","volume":"144","author":"Nishimura","year":"1999","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib10","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/oxfordjournals.eurheartj.a015282","article-title":"Improvement of myocardial perfusion after low-density lipoprotein apheresis treatment","volume":"18","author":"Jovin","year":"1997","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1526-0968.2003.00120.x","article-title":"State of the art of low-density lipoprotein apheresis in the year 2003","volume":"8","author":"Bosch","year":"2004","journal-title":"Ther Apher Dial"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/ncpcardio1456","article-title":"Longitudinal cohort study on the effectiveness of lipoprotein apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.transci.2004.03.006","article-title":"Internet-based quality assurance registry for LDL apheresis QUASA\u2013the apheresis registry","volume":"33","author":"Drager","year":"2005","journal-title":"Transfus Apher Sci"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/hrt.47.3.239","article-title":"Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction","volume":"47","author":"de Beer","year":"1982","journal-title":"Br Heart J"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0021-9150(01)00633-5","article-title":"C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis","volume":"158","author":"Moriarty","year":"2001","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0021-9150(01)00698-0","article-title":"Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis","volume":"162","author":"Wieland","year":"2002","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/jca.20033","article-title":"LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects","volume":"20","author":"Kobayashi","year":"2005","journal-title":"J Clin Apher"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.33549\/physiolres.930460","article-title":"Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity","volume":"53","author":"Blaha","year":"2004","journal-title":"Physiol Res"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0021-9150(98)00152-X","article-title":"LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia","volume":"141","author":"Rovers","year":"1998","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/ki.1985.136","article-title":"Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in\u00a0vivo and in\u00a0vitro within microamounts of whole blood","volume":"28","author":"Nguyen","year":"1985","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0022-2275(20)32381-6","article-title":"Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia","volume":"41","author":"Schamberger","year":"2000","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0021-9150(96)05919-9","article-title":"Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment","volume":"126","author":"Leitinger","year":"1996","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1091-6660.1999.t01-3-.x","article-title":"Review: the oxidant\/antioxidant balance during regular low density lipoprotein apheresis","volume":"3","author":"Schettler","year":"1999","journal-title":"Ther Apher"},{"issue":"4","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib25","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bbrc.2005.07.035","article-title":"The structure and function of oxidized albumin in hemodialysis patients: its role in elevated oxidative stress via neutrophil burst","volume":"334","author":"Mera","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"84","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib26","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1046\/j.1523-1755.63.s84.47.x","article-title":"Are advanced oxidation protein products potential uremic toxins?","author":"Witko-Sarsat","year":"2003","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0021-9150(98)00055-0","article-title":"Improvement of coronary vasodilatation capacity through single LDL apheresis","volume":"139","author":"Mellwig","year":"1998","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(98)00144-0","article-title":"Effects of lipids and lipoproteins on thrombosis and rheology","volume":"140","author":"Rosenson","year":"1998","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib29","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2362.2004.01341.x","article-title":"Increased red blood cell adhesiveness\/aggregation owing to fibrinogen elevation in hypercholesterolaemic patients and the rationale of fibrinogen-lowering by LDL apheresis","volume":"34","author":"Schuff-Werner","year":"2004","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1046\/j.1526-0968.2001.005001002.x","article-title":"Acute changes in plasma levels of hepatocyte growth factor during low-density lipoprotein apheresis","volume":"5","author":"Kojima","year":"2001","journal-title":"Ther Apher"},{"issue":"3","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jca.20047","article-title":"Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD)","volume":"20","author":"Pulido","year":"2005","journal-title":"J Clin Apher"},{"issue":"9348","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib32","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(02)11768-5","article-title":"Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial","volume":"360","author":"Suckfull","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib33","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1046\/j.1523-1755.1999.00791.x","article-title":"Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor","volume":"56","author":"Rampino","year":"1999","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/MOL.0b013e32834aa0c2","article-title":"The autoimmune concept of atherosclerosis","volume":"22","author":"Grundtman","year":"2011","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/jemt.10098","article-title":"Oxidative stress in phagocytes\u2013\u201cthe enemy within\u201d","volume":"57","author":"Splettstoesser","year":"2002","journal-title":"Microsc Res Tech"},{"issue":"1","key":"10.1016\/j.atherosclerosissup.2012.10.017_bib36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1744-9987.2010.00861.x","article-title":"Impact of lipoprotein apheresis on Egr-1, c-Jun, c-Fos, and Hsp70 gene expression in white blood cells","volume":"15","author":"Schettler","year":"2011","journal-title":"Ther Apher Dial"}],"container-title":["Atherosclerosis Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567568812000281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:04:56Z","timestamp":1687997096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567568812000281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1567568812000281"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosissup.2012.10.017","relation":{},"ISSN":["1567-5688"],"issn-type":[{"value":"1567-5688","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}